论文部分内容阅读
目的观察ＩＬ－２真核表达载体（ｐＷＲＧ３１６９）对ＨＢＶ－Ｓ ＤＮＡ疫苗（ｐＣＲ ３．１－Ｓ）诱导Ｂａｌｂ／ｃ小鼠（Ｈ－２~ｄ）的 特异性细胞免疫应答及其对稳定表达ＨＢｓＡｇ的小鼠肥大细胞瘤Ｐ８１５细胞（Ｐ８１５－ＨＢＶ－Ｓ）成瘤性的影响。方法肌肉注射ＤＮＡ疫苗，背部皮下接种Ｐ８１５－ＨＢＶ－Ｓ细胞，观察成瘤情况，４ ｈ~（５１）Ｃｒ释放法检测小鼠脾细胞 ＣＦＬ活性。结果对照组、ｐＣＲ ３．１－ Ｓ及共同免疫 ＩＬ－ １２组成瘤率为 １００％，１２％和 ０，４５ ｄ后小鼠存活率为 ０，８８％及 １００％，平均存活期分别为２８．４ｄ，≥２３８．２ｄ及≥４５ｄ。ｐＣＲ３．１－Ｓ组ＣＴＬ细胞杀伤活性５１．１％，联合ＩＬ－１２真核表达载体组７２．６％，对照组为２０．５％（Ｐ＜０．０１）。结论ＤＮＡ疫苗可以诱导小鼠细胞免疫应答，对体内ＨＢＶ感染具有预防反治疗作用。ＵＬ－１２真核表达载体可加强ＤＮＡ疫苗的上述作用。
Objective To observe the specific cellular immune response of IL-2 eukaryotic expression vector (pWRG3169) to Balb / c mice (H-2 ~ d) induced by HBV-S DNA vaccine (pCR 3.1-S) Effect of HBsAg on tumorigenesis of mouse mastocytoma P815 cells (P815-HBV-S). Methods Mice were injected intramuscularly with DNA vaccine and P815-HBV-S cells were inoculated subcutaneously in the back. The tumorigenesis was observed. The CFL activity of splenocytes was detected by 4 h ~ (51) Cr release assay. RESULTS: The control group, pCR 3.1-S and co-immunized IL-12 had a tumorigenic rate of 100%. After 12 and 0,45 days, the survival rates of mice were 0, 88% and 100%, respectively, with mean survival of 28 .4d, ≥238.2d and ≥45d. The cytotoxic activity of CTL in pCR3.1-S group was 51.1%, which was 72.6% in combination with IL-12 eukaryotic expression vector group and 20.5% in control group (P <0.01). Conclusion DNA vaccine can induce cellular immune response in mice and prevent anti-HBV therapy in vivo. The UL-12 eukaryotic expression vector enhances the above effects of DNA vaccines.